Table 2. Univariate and multivariate analysis of disease-free survival in HCC patients.
| Clinicopathologic parameters | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Age (<60 vs. ≥60 years) | 0.976 (0.531–1.791) | 0.936 | – | – | |
| Gender (female vs. male) | 0.685 (0.269–1.749) | 0.429 | – | – | |
| Hepatitis B (negative vs. positive) | 1.631 (0.725–3.669) | 0.237 | – | – | |
| AFP (<400 vs. ≥400 ng/L) | 1.015 (0.540–1.908) | 0.962 | – | – | |
| Microvascular invasion (present vs. absent) | 1.628 (0.632–4.191) | 0.312 | – | – | |
| Capsular invasion (present vs. absent) | 1.276 (0.697–2.336) | 0.429 | – | – | |
| Tumor diameter (<5 vs. ≥5 cm) | 1.136 (0.583–2.214) | 0.709 | – | – | |
| Multiple lesions (present vs. absent) | 1.136 (0.544–2.374) | 0.734 | – | – | |
| Vessel carcinoma embolus (present vs. absent) | 3.154 (1.672–5.951) | <0.001 | 1.745 (0.893–3.411) | 0.103 | |
| Cirrhosis (present vs. absent) | 2.088 (1.097–3.973) | 0.025 | 1.948 (1.007–3.771) | 0.048* | |
| Tumor differentiation (low vs. high/moderate) | 0.551 (0.298–1.021) | 0.058 | 0.407 (0.192–0.859) | 0.018* | |
| TNM stage (I–II vs. III–IV) | 2.432 (1.302–4.542) | 0.005 | 2.703 (1.255–5.818) | 0.011* | |
| RNU5E-1 expression (low vs. high) | 0.252 (0.130–0.488) | <0.001 | 0.375 (0.185–0.760) | 0.006* | |
*, P<0.05 was considered to be statistically significant. AFP, alpha fetal protein; TNM, tumor-node-metastasis; HR, hazard ratio; CI, confidence interval; HCC, hepatocellular carcinoma.